Flangea Corina, Potencz Elena, Mihăescu Rodica, Anghel A, Gîju S, Motoc Marilena, Dogaru C
Department of Biochemistry, "Victor Babeş" University of Medicine and Pharmacy Timişoara, Timişoara.
Rom J Morphol Embryol. 2006;47(2):113-7.
The presence of Reed-Sternberg malignant cells is absolutely necessary for Hodgkin's lymphoma diagnostic, but it is not always sufficient because can be observed Reed-Sternberg-like cells in other malignant and benign diseases, too. The CD30 expression at Hodgkin and Reed-Sternberg level can give us supplementary information in differential diagnostic and can be used as progressive disease factor.
Our study was composed from 63 cases histopathological diagnosed with Hodgkin's lymphoma and hospitalized in Hematology Department of County Hospital Timişoara. CD30 expression was immunohistochemical semi-quantitative evaluated using clone BerH2 as primary antibody and APAAP-New Fuchsin as visualization system.
The increasing of CD30 expression occurs in the same time with advanced stages and the disease progression (p =0.001). For I and II stages CD30 expression does not overcome (-/+) category while the III and IV stages, all the cases are situated in (+/-) and (+) categories. No connection can be noticed between histological type and CD30 expression (p < or = 1). We consider that using this staining, although less used in Romania, must be done in all Hodgkin's lymphoma and Hodgkin's lymphoma-like cases. We say that because the main cause of relapses is represented by inadequate clinical staging and diagnostic.
In our study, the increasing of CD30 expression is associated with advanced disease stage. We recommend reinvestigating and restaging all cases that was included into an incipient stages and they have a CD30 expression situated in (+/-) and (+) intervals because some lymph nodes could be overlooked.
里德-施特恩伯格恶性细胞的存在对于霍奇金淋巴瘤的诊断绝对必要,但并不总是充分的,因为在其他恶性和良性疾病中也可观察到里德-施特恩伯格样细胞。霍奇金和里德-施特恩伯格水平的CD30表达可为鉴别诊断提供补充信息,并可作为疾病进展因素。
我们的研究由63例经组织病理学诊断为霍奇金淋巴瘤并在蒂米什瓦拉县医院血液科住院的病例组成。使用克隆BerH2作为一抗,APAAP-新复红作为可视化系统,对CD30表达进行免疫组织化学半定量评估。
CD30表达的增加与疾病晚期和进展同时出现(p = 0.001)。对于I期和II期,CD30表达未超过(-/+)类别,而III期和IV期,所有病例均处于(+/-)和(+)类别。未发现组织学类型与CD30表达之间存在关联(p≤1)。我们认为,尽管在罗马尼亚较少使用这种染色,但在所有霍奇金淋巴瘤和霍奇金淋巴瘤样病例中都必须进行。我们这样说是因为复发的主要原因是临床分期和诊断不足。
在我们的研究中,CD30表达的增加与疾病晚期相关。我们建议对所有最初被纳入早期且CD30表达处于(+/-)和(+)区间的病例进行重新检查和重新分期,因为可能会遗漏一些淋巴结。